Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px
All >

Deals > Switzerland

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Switzerland or involving Swiss organisations.

Total search results: 1161 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Adrenomed–Informa: investor conference, 201905 supply service Adrenomed presents at BioEquity Europe 2019 in Barcelona 2019-05-20
JnJ–Owlstone: breath analyser, 201905– collab developm breath-based test for early detection of pulmonary hypertension with Actelion 2019-05-20
Therachon–Cowen: investment, 201905 existing investor Cowen 2019-05-08
Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative 2019-05-08
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings 2019-05-08
Therachon–OrbiMed: investment, 201905 existing investor OrbiMed 2019-05-08
Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures 2019-05-08
Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program 2019-05-08
Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC 2019-05-08
Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures 2019-05-08
Chemical Solutions Ltd–SGS: investment, 201905 acquisition of CSL by SGS 2019-05-03
Amal Therapeutics–Boehringer: cancer drugs, 201905– collab clinical research combi study of ATP128 + BI754091 in colorectal cancer 2019-05-02
Alentis Therapeutics–Bellevue: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BB Pureos Bioventures 2019-04-30
Alentis Therapeutics–BioMedPartners: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BioMedPartners 2019-04-30
Alentis Therapeutics–France (govt): investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Bpifrance 2019-04-30
Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif 2019-04-30
Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq 2019-04-30
Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures 2019-04-30
SGS–Veeva Systems: clinical research software, 201904– supply global implementation of Veeva Vault CTMS by SGS 2019-04-30
ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development 2019-04-24
Poseida Therapeutics–Novartis: investment, 201904 financing round Series C totalling $142m incl $75m from lead investor Novartis Pharma AG 2019-04-22
Arrakis Therapeutics–HBM: investment, 201904 financing round Series B totalling $75m incl new + co- investor HBM Healthcare Investments 2019-04-18
Arrakis Therapeutics–Nextech Invest: investment, 201904 financing round Series B totalling $75m incl co-lead investor Nextech Invest 2019-04-18
ETH Zürich–Agilent: mass spectrometer, 201904 supply new 6546 LC/Q-TOF MS system to lab of Nicola Zamboni 2019-04-15
DKSH–Bruker Corp: analytical instruments, 201904– distribution excl extension for Bruker AXS products by DKSH in China 2019-04-09
Chr Hansen–Lonza: live biotherapeutics, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments 2019-04-02
IFM Therapeutics–Novartis: investment, 201904– acquisition 100% of IMF Tre for upfront payment + milestones ANNOUNCED 2019-04-01
Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA 2019-03-28
Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA 2019-03-28
Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners 2019-03-28
Qiagen–Tecan: lab automation, 201903– collab direct supply of Tecan Fluent workstation for sample to labs using QuantiFeron-TB Gold Plus test 2019-03-08
NovaGo Therapeutics–Neurimmune: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor + strategic partner Neurimmune 2019-03-04
NovaGo Therapeutics–Pureos Bioventures: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor Pureos Bioventures 2019-03-04
NovaGo Therapeutics–SEVERAL: investment, 201903 financing round Series A CHF10m co-led by Pureos Bioventures + Neurimmune 2019-03-04
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
Anaveon–Novartis: investment, 201902 financing round Series A totalling CHF35m incl co-investor Novartis Venture Fund 2019-02-26
Anaveon–SEVERAL: investment, 201902 financing round Series A CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Roche–Citigroup: financial services, 201902 supply Citi financial advisor to Roche with regard to acquisition of Spark by Roche 2019-02-25
Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics 2019-02-25
Spark Therapeutics–Roche: investment, 201902– acquisition $4.3b cash tender offer for all shares at $114.5/share ANNOUNCED 2019-02-25
CRISPR Therapeutics–StrideBio: AAV vectors, 201902– collab expansion €na of developm + license option usingStrideBio’s vectors for CRISPR therapies 2019-02-19
Gain Therapeutics–Fondazione Centenario BancaStato: investment, 201902 financing round Series A totalling €2.5m incl €400k from TiVenture SA 2019-02-19
Gain Therapeutics–Helsinn: investment, 201902 financing round Series A totalling €2.5m incl €1m from new investor Helsinn Investment Fund SA 2019-02-19
Gain Therapeutics–SEVERAL: investment, 201902 financing round Series A €2.5m from VitaTech + Helsinn Investment Fund + TiVenture 2019-02-19
Gain Therapeutics–VitaTech: investment, 201902 financing round Series A totalling €2.5m incl €1.1m from new investor VitaTech SA 2019-02-19
S-Biomedic–Verve Capital Partners: investment, 201902 financing round Series A 2nd closing totalling €2m incl existing investor investiere.ch 2019-02-18
Arvelle Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling $180m incl investor Andera Partners 2019-02-14
Arvelle Therapeutics–BRV Capital: investment, 201902 financing round Series A totalling $180m incl investor BRV Capital Management 2019-02-14
Arvelle Therapeutics–H.I.G. Capital: investment, 201902 financing round Series A totalling $180m incl investor H.I.G. BioHealth Partners 2019-02-14
Arvelle Therapeutics–Life Sciences Partners: investment, 201902 financing round Series A totalling $180m incl lead investor LSP 2019-02-14
Arvelle Therapeutics–NovaQuest Capital: investment, 201902 financing round Series A totalling $180m incl investor NovaQuest Capital Management 2019-02-14
Arvelle Therapeutics–Sam Brown: public relations, 201902 service existent by Sam Brown Inc 2019-02-14
Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate 2019-02-14
Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals 2019-02-14
Novartis–AbCellera: therapeutic antibodies, 201902– collab discovery use of AbCellera technology + screening for up to ten targets 2019-02-14
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research 2019-02-06
Bruker Corp–Genedata: bioinformatics, 201902 collab product integration Bruker new Ready-to-Run partner 2019-02-05
Macherey-Nagel–Andrew Alliance: automated liquid handling technology, 201902–collab co-marketing NucleoBond kits with OneLab s/w + Andrew+ robot 2019-02-04
CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR 2019-01-22
Scailyte–SEVERAL: investment, 201901 seed financing round CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Swisscom: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Zürcher Kantonalbank: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
InterAx Biotech–Falcon III Ventures: investment, 201901 financing round totalling CHF3m incl co-lead investor Falcon III Ventures 2019-01-15
InterAx Biotech–SEVERAL: investment, 201901 financing round CHF3m led by Falcon III Ventures + Investiere 2019-01-15
InterAx Biotech–Verve Capital Partners: investment, 201901 financing round totalling CHF3m incl co-lead investor Investiere 2019-01-15
Tecan–JPMorgan Chase: investor conference, 201901 supply service Tecan Group presents at JP Morgan Healthcare Conference 2019 2019-01-10
Agenus–JSR Corp: cell line development, 201901– collab expansion license to use Selexis’ SUREtechnology for production of therapeutic proteins 2019-01-09
BC Platforms–MedEngine (FI): medical data science services, 201901– collab strategic partnership to provide solutions for pharma + health sectors 2019-01-09
Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates 2019-01-07
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Evitria–Afinum: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
Evitria–SHS: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
Annexon Biosciences–Novartis: investment, 201812 financing round Series C totalling $75m incl exisiting + co-investor NVF 2018-12-19
Cellestia Biotech–PPF Group: investment, 201812 financing round Series A totalling CHF20m incl existing + co-lead investor Sotio/PPF Group 2018-12-19
Cellestia Biotech–SEVERAL: investment, 201812 financing round Series A CHF20m from FC Capital + Sotio/PPF Group + ETP Ventures + private investors 2018-12-19
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 2018-12-18
Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech 2018-12-13
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership 2018-12-12
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing 2018-12-12
Novartis–Qiagen: molecular companion diagnostics, 201812– collab developm of CDx for alpelisib (BYL719) 2018-12-06
AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA 2018-12-05
JnJ–Argenx: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
CRISPR Therapeutics–Barclays: investor conference, 201811 supply service CRISPR Tx presents at Barclays Gene Editing & Gene Therapy Summit 2018-11-29
CRISPR Therapeutics–Piper Jaffray: investor conference, 201811 supply service CRISPR Therapeutics at Piper Jaffray Healthcare Conference 2018 2018-11-28
Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments 2018-11-26
Inflazome–Novartis: investment, 201811 financing round Series B totalling €40m incl existing + co-investor Novartis Venture Fund 2018-11-19
Cadent Therapeutics–Novartis: investment, 201811 financing round Series B totalling $40m incl co-investor Novartis Institutes for Biomedical Research 2018-11-15
Argenx–Credit Suisse: investor conference, 201811 supply service Argenx presents at Credit Suisse Annual Healthcare Conference 2018 2018-11-14
Roivant–SEVERAL: investment, 201811 financing round $200m led by new investors NovaQuest Capital Management + RTW Investments 2018-11-13
Aimmune Therapeutics–Nestlé: investment, 201811 equity investment $98m w 3.24m shares at $30.27/share by Nestlé Health Science brings stake to 19% 2018-11-12
Amal Therapeutics–SEVERAL: investment, 201811 financing round Series B 2nd + final closing €21.2m co-led by BIVF + BioMedPartners + Helsinn 2018-11-12
CRISPR Therapeutics–MaxCyte: gene transfer technology, 201811– license commercial to use Flow Electroporation techn for CRISPR-based I-O therapies 2018-11-09
1 2 3 4 5 6 7 8 9 10 11 12  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top